Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$85.72

-0.14 (-0.16%)

08:26
12/12/18
12/12
08:26
12/12/18
08:26

Stifel would be buying Neurocrine on pullback after Tourette's failure surprise

After Neurocrine announced its Phase IIb T-Force GOLD study for valbenazine in pediatric Tourette Syndrome did not meet its primary endpoint, Stifel analyst Paul Matteis said he was " surprised and disappointed" by the study failure and admits he was wrong to have been optimistic with his 75% probability-of-success odds. He has previously written that Neurocrine shares could be down 15% on a negative study, but noted that was pinned to a higher valuation for the stock. In such a scenario, he would be buying the stock on weakness, said Matteis, who keeps a Buy rating on Neurocrine shares. In pre-market trading, the stock is down $15.24, or 18%, to $70.52.

  • 12

    Dec

NBIX Neurocrine
$85.72

-0.14 (-0.16%)

11/13/18
LEER
11/13/18
INITIATION
Target $110
LEER
Market Perform
Neurocrine initiated with a Market Perform at Leerink
Leerink analyst Marc Goodman started Neurocrine with a Market Perform and $110 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Neurocrine, Goodman believes Ingrezza should be a significant product for TD/TS but consensus sales expectations are already high.
11/15/18
JEFF
11/15/18
NO CHANGE
Target $131
JEFF
Buy
Jefferies says buy Neurocrine after yesterday's 'unwarranted' selloff
Jefferies analyst Biren Amin tells investors to buy shares of Neurocrine Biosciences after hosting a dinner with management. Management shared thoughts on the Ingrezza launch and dispelled recent safety concerns, noting the company rigorously reports the majority of adverse events found in the FDA database and that none of the 88 deaths reported are due to Ingrezza, Amin tells investors in a research note. Further, the analyst thinks the risk/reward on shares into the December Tourettes data is "significant to the upside." Amin views yesterday's selloff as "unwarranted" and keeps a Buy rating on Neurocrine with a $131 price target. The stock closed yesterday down 13%, or $13.37, to $86.13.
11/15/18
BARD
11/15/18
NO CHANGE
Target $131
BARD
Outperform
Neurocrine elevated to Fresh Pick, FAERS fears unwarranted, says Baird
Baird analyst Brian Skorney elevated Neurocrine to Fresh Pick and said to take advantage of the unwarranted fear caused by the FDA's FAERS update. The analyst said the update was a regular update to their database and it did yield a numerically higher number of patient deaths. However, he said this is typical because as the number of Ingrezza prescriptions increase, so will the number of incidents. He believes this caused an overreaction and investors should take advantage of the buying opportunity. Skorney reiterated his Outperform rating and $131 price target on Neurocrine shares.
11/21/18
ADAM
11/21/18
INITIATION
Target $111
ADAM
Buy
Neurocrine initiated with a Buy at Canaccord
Canaccord analyst Sumant Kulkarni initiated Neurocrine with a Buy rating as he said the company is one of the few where a product launch exceeded expectations. He said he is guardedly optimistic heading into Phase 2b data for Ingrezza in pediatric Tourette syndrome and with the stock's recent pullback, he sees an attractive entry point. He also thinks the pullback could cause investors to look at Neurocrine to be involved in industry consolidation. Kulkarni set a $111 price target on Neurocrine shares.

TODAY'S FREE FLY STORIES

02:00
10/16/19
10/16
02:00
10/16/19
02:00
General news
U.S. Retail Sales Preview: »

U.S. Retail Sales…

01:50
10/16/19
10/16
01:50
10/16/19
01:50
General news
Asian Market Update: »

Asian Market Update:…

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

, SPX

S&P 500

$0.00

(0.00%)

20:46
10/15/19
10/15
20:46
10/15/19
20:46
Periodicals
China may retaliate if U.S. Congress passes bill supporting Hong Kong protesters 

Report from Bloomberg.

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.74

0.59 (2.02%)

, ABT

Abbott

$82.06

2.25 (2.82%)

20:25
10/15/19
10/15
20:25
10/15/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$29.74

0.59 (2.02%)

ABT

Abbott

$82.06

2.25 (2.82%)

USB

U.S. Bancorp

$53.73

0.47 (0.88%)

PNC

PNC Financial

$141.86

1.38 (0.98%)

BK

BNY Mellon

$44.37

0.47 (1.07%)

ALLY

Ally Financial

$32.03

0.68 (2.17%)

CMA

Comerica

$67.01

1.765 (2.71%)

FHN

First Horizon

$16.13

0.22 (1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 27

    Oct

  • 07

    Nov

  • 12

    Nov

RIO

Rio Tinto

$51.40

-0.43 (-0.83%)

20:17
10/15/19
10/15
20:17
10/15/19
20:17
Hot Stocks
Rio Tinto reports Q3 Pilbara iron ore output 87.3M tons, up 6% from last year »

Reports Q3 Pilbara iron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNTX

Gentex

$26.98

0.65 (2.47%)

20:16
10/15/19
10/15
20:16
10/15/19
20:16
Initiation
Gentex initiated at Guggenheim »

Gentex initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 04

    Nov

VNE

Veoneer

$16.11

0.82 (5.36%)

20:16
10/15/19
10/15
20:16
10/15/19
20:16
Initiation
Veoneer initiated at Guggenheim »

Veoneer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

VC

Visteon

$82.45

0.63 (0.77%)

20:15
10/15/19
10/15
20:15
10/15/19
20:15
Initiation
Visteon initiated at Guggenheim »

Visteon initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

DLPH

Delphi Technologies

$14.37

0.45 (3.23%)

20:14
10/15/19
10/15
20:14
10/15/19
20:14
Initiation
Delphi Technologies initiated at Guggenheim »

Delphi Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

BWA

BorgWarner

$37.74

0.68 (1.83%)

20:13
10/15/19
10/15
20:13
10/15/19
20:13
Initiation
BorgWarner initiated at Guggenheim »

BorgWarner initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

LEA

Lear

$121.75

3.94 (3.34%)

20:13
10/15/19
10/15
20:13
10/15/19
20:13
Initiation
Lear initiated at Guggenheim »

Lear initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 04

    Nov

  • 10

    Dec

  • 11

    Dec

DFIN

Donnelley Financial Solutions

$10.54

0.035 (0.33%)

20:12
10/15/19
10/15
20:12
10/15/19
20:12
Initiation
Donnelley Financial Solutions initiated at B. Riley FBR »

Donnelley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.84

2.17 (1.66%)

, TEVA

Teva

$6.96

0.22 (3.26%)

19:17
10/15/19
10/15
19:17
10/15/19
19:17
Periodicals
As part of proposed settlement, Teva offers $15B of free drugs, Bloomberg says »

The report also notes…

JNJ

Johnson & Johnson

$132.84

2.17 (1.66%)

TEVA

Teva

$6.96

0.22 (3.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 07

    Nov

WAFD

Washington Federal

$36.81

0.15 (0.41%)

19:04
10/15/19
10/15
19:04
10/15/19
19:04
Earnings
Washington Federal reports Q4 EPS 66c, consensus 65c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

INGR

Ingredion

$81.17

0.94 (1.17%)

19:01
10/15/19
10/15
19:01
10/15/19
19:01
Hot Stocks
Ingredion discloses malware affecting certain data centers »

Ingredion issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

19:01
10/15/19
10/15
19:01
10/15/19
19:01
Periodicals
Pelosi holds off on House vote over impeachment inquiry, Politico says »

House Speaker Nancy…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.40

0.02 (0.14%)

18:59
10/15/19
10/15
18:59
10/15/19
18:59
Hot Stocks
Petrobras signs charter contracts for two FPSO platforms »

Petrobras announced that …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

SNBR

Sleep Number

$46.69

0.48 (1.04%)

, UAL

United Airlines

$87.90

0.9 (1.03%)

18:58
10/15/19
10/15
18:58
10/15/19
18:58
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Sleep…

SNBR

Sleep Number

$46.69

0.48 (1.04%)

UAL

United Airlines

$87.90

0.9 (1.03%)

MCK

McKesson

$138.17

4.01 (2.99%)

ABC

AmerisourceBergen

$83.18

1.6 (1.96%)

CAH

Cardinal Health

$47.93

1.16 (2.48%)

FULT

Fulton Financial

$15.90

0.19 (1.21%)

ETN

Eaton

$82.16

1.29 (1.60%)

SFIX

Stitch Fix

$20.83

-0.38 (-1.79%)

MGM

MGM Resorts

$27.87

-0.1 (-0.36%)

JBHT

J.B. Hunt

$111.65

1.985 (1.81%)

IBKR

Interactive Brokers

$47.43

0.26 (0.55%)

RYTM

Rhythm Pharmaceuticals

$20.90

0.52 (2.55%)

PRQR

ProQR Therapeutics

$6.21

-0.09 (-1.43%)

NTRA

Natera

$39.21

1.01 (2.64%)

PRNB

Principia Biopharma

$29.88

0.7 (2.40%)

X

U.S. Steel

$11.43

0.27 (2.42%)

ARCE

Arco Platform

$48.15

0.75 (1.58%)

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 18

    Oct

KKR

KKR

$26.79

0.67 (2.57%)

, DB

Deutsche Bank

$7.79

0.235 (3.11%)

18:21
10/15/19
10/15
18:21
10/15/19
18:21
Periodicals
KKR, partners cancel Latitude Financial IPO, Reuters reports »

KKR (KKR) and its…

KKR

KKR

$26.79

0.67 (2.57%)

DB

Deutsche Bank

$7.79

0.235 (3.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 29

    Oct

  • 04

    Nov

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:20
10/15/19
10/15
18:20
10/15/19
18:20
Hot Stocks
Breaking Hot Stocks news story on Tradeweb Markets »

Tradeweb Markets sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:17
10/15/19
10/15
18:17
10/15/19
18:17
Syndicate
Tradeweb Markets files to sell 14.8M shares of Class A common stock »

Refinitiv will continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:16
10/15/19
10/15
18:16
10/15/19
18:16
Earnings
Tradeweb Markets sees Q3 adjusted EPS 27c, consensus 25c »

Sees Q3 revenue $200.98M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

EDIT

Editas Medicine

$20.30

0.48 (2.42%)

18:15
10/15/19
10/15
18:15
10/15/19
18:15
Hot Stocks
Editas Medicine, AskBio enter research collaboration over in vivo delivery »

Editas Medicine and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$114.78

2.43 (2.16%)

18:03
10/15/19
10/15
18:03
10/15/19
18:03
Periodicals
NV regulators want to ban Steve Wynn from NV casino industry, Reuters says »

The Nevada Gaming Control…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$20.83

-0.38 (-1.79%)

18:00
10/15/19
10/15
18:00
10/15/19
18:00
Hot Stocks
Stitch Fix director buys 150K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.